Basic and clinical studies on grepafloxacin in surgery
スポンサーリンク
概要
- 論文の詳細を見る
A newly developed pyridone carboxylic acid antimicrobial drug for oral use in surgery, grepafloxacin GPFX), was studied basically and clinically, with the following results:<BR>1) Antibacterial activity: Minimum 50% inhibitory concentration/minimum 90% inhibitory concentration (MIC<SUB>50</SUB>/MIC<SUB>90</SUB>)(μg/ml) against <I>Staphylococcus aureus</I> (20 strains), <I>Escherichia coli</I> (20 strains), <I>Klebsiella pneumoniae</I> (12 strains) and <I>Pseudomonas aeruginosa</I> (20 strains), which were isolated from surgical lesions, were 0.39/3.13, ≤0.2/3.13, ≤0.2/≤0.2, and 0.78/3.13, respectively. There were any sensitive strains of <I>P. aeruginosa</I>.<BR>2) Results of clinical use: In 21 patients with surgical infectious diseases, the drug was markedly effective in 9, effective in 6, slightly effective in 1, ineffective in 4, and unevaluable in 1. Bacteriologically, 23 of the 27 strains were eradicated, and the eradication rate was 85.2%. As an objective adverse reaction, exanthema appeared in one patient with lymphadenitis. After the discontinuation of administration, the exanthema disappeared. No abnormal changes were observed on clinical laboratory tests.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.